Clinical trials: Neoadjuvant Therapies
Breast Cancer
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer
The aim of this project is to evaluate tailored primary systemic therapy with sequential nab paclitaxel and epirubicin and cyclophosphamide in early breast cancer. This study will be an open label phase II clinical trial.
- Trial name
- Neonab (NCT01830244)
- Testing
- Nab-Paclitaxel
- Where
- 5 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Barwon Health
Ovarian Cancer, Stage III Ovarian Cancer
Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy
The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.
- Conditions
- Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT04204811
- Testing
- Prehabilitation
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Cancer, Neoadjuvant Chemotherapy
Comparison of the Pathological Effect Between 2 and 4 Cycles Neoadjuvant CAPOX for Low/Intermediate Risk II/III Rectal Cancer
To compare the pathological effect between 2 cycles and 4 cycles of Capox regimen as neoadjuvant chemotherapy for low/ intermediate risk stage II/III rectal cancer.
- Trial name
- COPEC (NCT04922853)
- Testing
- Capox chemotherapy
- Where
- 4 sites in China
- Volunteers
- 554 people
- Sponsor
- West China Hospital
HER2-positive Breast Cancer
Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
Neratinib is an oral, irreversible pan-HER tyrosine kinase inhibitor. Current treatment guidelines recommend neratinib as an extended adjuvant therapy for HER2-positive breast cancer patients to further reduce the risk of…
- Trial name
- NCT07019272
- Testing
- Neratinib (HKI-272)
- Volunteers
- 170 people
- Sponsor
- Hebei Medical University Fourth Hospital
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
To explore the efficacy and safety of neoadjuvant furmonertinib combined with bevacizumab in the treatment of resectable and potentially resectable stage III-IVA EGFR mutation-positive lung adenocarcinoma.
- Conditions
- Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
- Trial name
- NCT05503667
- Testing
- Furmonertinib, Bevacizumab
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Breast Cancer
Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy
This research protocol is studying the accuracy of the sentinel lymph node biopsy procedure in breast cancer patients who have cancer cells in the lymph nodes in the armpit (axilla) who have received chemotherapy or endocrine…
- Trial name
- NCT02752009
- Testing
- Axillary Lymph Node Sampling Clip
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT05710328
- Testing
- Chemotherapy, Computed Tomography, Fludeoxyglucose F-18
- Where
- 102 sites in United States, Puerto Rico
- Volunteers
- 235 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Liver Metastases, Recurrent Colon Cancer
Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
Drugs used in chemotherapy, such as capecitabine and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00070265
- Testing
- oxaliplatin, capecitabine, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma
With this trial, we aim to evaluate a new combination therapy with tislelizumab and FLOT chemotherapy before surgery (neoadjuvant) for locally advanced, resectable adenocarcinoma of the esophagus or stomach (EGA).
- Conditions
- Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Resectable Esophagogastric Adenocarcinoma
- Trial name
- NeoTISLEGA (NCT07059299)
- Testing
- Tislelizumab, FLOT Chemotherapy
- Where
- 4 sites in Germany
- Volunteers
- 18 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Breast Cancer
Mini-invasive Detection of Residual Disease in Breast Cancer Patients in Remission After Primary Chemotherapy
Breast surgery may be overtreatment when there is a complete response to systemic neoadjuvant treatment as determined clinically and by imaging.
- Trial name
- NCT05951699
- Testing
- minimally invasive preoperative image-guided vacuum-assisted biopsy
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
MelanomaCutaneous Melanoma Resectable, Melanoma
Neoadjuvant RP2 + Nivolumab in Patients With Melanoma
This is a Phase II study is being done to determine whether a new combination of therapies is safe and effective for adults to treat Melanoma before surgery.
- Trial name
- NCT07862530
- Testing
- RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yana Najjar
Breast Cancer, Breast Neoplasms
Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country
This study evaluates the feasibility and efficacy of neoadjuvant tamoxifen for patients with locally advanced hormone receptor positive breast cancer in a low/middle income country.
- Trial name
- NCT02806544
- Testing
- Tamoxifen
- Volunteers
- 35 people
- Sponsor
- Vanderbilt University
Gastric Cancer
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
Recently, a number of clinical studies were carried out to evaluate the therapeutic effects of PD-1 antibodies combined with chemotherapy as preoperative neoadjuvant therapy of gastric cancer (GC) worldwide.
- Trial name
- NCT05594381
- Testing
- Sintilimab
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Glioblastoma
Preoperative Preradiotherapy TTFields
PreOperative PreRAdIotherapy Tumour Treating Fields (PORTRAIT) is a Phase I study that will test the safety and feasibility of Optune administered preoperatively and preradiotherapy in patients with a new radiological diagnosis…
- Trial name
- PORTRAIT (NCT06136611)
- Testing
- TTFields
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- The Christie NHS Foundation Trust
Multiple Myeloma
A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
- Trial name
- NCT00057564
- Testing
- A (Thalidomide + Dexamethasone)
- Where
- 99 sites in United States, Australia and 14 more
- Volunteers
- 470 people
- Sponsor
- Celgene Corporation
Lung Cancer, Non-small Cell Lung Cancer
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
- Trial name
- NCT06877299
- Testing
- Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Solid Tumor
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer
This is an prospective, multicenter, single-arm clinical study.
- Trial name
- NCT05525767
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Hebei Medical University Fourth Hospital
Venous Thromboembolism
Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Interventional, no-randomized, open-label, and single arm multicentre study of apixaban for the prevention of thromboembolic events during induction therapy in transplant-eligible patients with newly diagnosed multiple myeloma…
- Trial name
- NCT04106700
- Testing
- Apixaban 2.5 MG
- Where
- 4 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Instituto de Investigacion Sanitaria La Fe
Renal Pelvis and Ureter Urothelial Carcinoma
Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
This phase II clinical trial tests how well pembrolizumab plus enfortumab vedotin prior to and after radical nephroureterectomy works in treating patients with high-risk upper tract urothelial cancer.
- Trial name
- NCT05775471
- Testing
- Biopsy, Biospecimen Collection, Enfortumab Vedotin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Hepatocellular Carcinoma (HCC)
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Objectives: 1. To evaluate the efficacy, in terms of tumor shrinkage, objective response rate, and down-stage rate, of nivolumab + ipilimumab as neoadjuvant therapy for patients with HCC; 2.
- Trial name
- NCT03510871
- Testing
- nivolumab, ipilimumab
- Where
- 8 sites in Taiwan
- Volunteers
- 43 people
- Sponsor
- National Health Research Institutes, Taiwan